Last reviewed · How we verify
NCT06878924: SAVIOR
Safety and Efficacy of Pulmonary Vein Isolation Using Pulsed-field Ablation (PFA) Combined with Either PFA-based Left Atrial Posterior Wall Isolation or Vein of Marshall Ethanol Ablation in Patients with Persistent Atrial Fibrillation
trial in Atrial Fibrillation (AF) in 162 participants. Not yet recruiting.
1 May 2027
Quick facts
| Lead sponsor | Texas Cardiac Arrhythmia Research Foundation |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 162 |
| Start date | 1 May 2025 |
| Primary completion | 1 May 2027 |
| Estimated completion | 1 December 2027 |
Conditions studied
- Atrial Fibrillation (AF) — all drugs for Atrial Fibrillation (AF) →
Sponsor
Texas Cardiac Arrhythmia Research Foundation
Who can join
Adults 18 to 85, any sex, with Atrial Fibrillation (AF). Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Recurrence of atrial arrhythmia: any episode of AF/AT longer than 30 sec off-AAD, after the 2-month blanking period
Time frame: 1 year
Sponsor's own description
This study is designed to directly compare the safety and efficacy of PFA-based PVI+PWI vs PFA-based PVI+ VoM alcohol ablation in patients with Persistent AF.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06878924
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Atrial Fibrillation (AF)
Currently open trials in the same condition.
- NCT07298473 — Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sp · NA · recruiting
- NCT07442175 — Blood Pressure Monitor (TH-75) Atrial Fibrillation Detection Function Clinical Trial · recruiting
- NCT07389434 — Feasibility, Safety, Cost-effectiveness, and Environmental Impact of Reprocessed Ablation Catheters in PVI · NA · recruiting
- NCT07250529 — Left Bundle Branch Pacing vs Right Ventricular Pacing on AHRE Burden in Patients With Preserved LVEF · NA · recruiting
- NCT07358611 — Non-invasive Mapping-Guided Atrial Fibrillation Ablation · NA · recruiting
Other Texas Cardiac Arrhythmia Research Foundation trials
Trials by the same sponsor.
- NCT06488820 — Safety and Efficacy of Pulsed-field Ablation for Atrial Fibrillation in High Versus Low-volume Ablation Centers (SAFFICI · terminated
- NCT04830774 — Natural History of COVID-19-Related Atrial Fibrillation · NA · unknown
- NCT04726943 — RF Applications for Residual LAA Leaks · NA · unknown
- NCT04502017 — Efficacy of Different Anti-Thrombotic Strategies on Device-Related Thrombosis Prevention After Percutaneous Left Atrial · Phase 4 · unknown
- NCT04352764 — ANTIBODY BASED TESTS FOR SARSCoV-2 COVID-19) - Evaluation of Patients and Healthcare Providers in the Confines of Health · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06878924 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Texas Cardiac Arrhythmia Research Foundation
- Last refreshed: 10 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06878924.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing